Truist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41

Benzinga · 2d ago
Truist Securities analyst Supawat Thongthip maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $40 to $41.